Abstract
Importance Accurate and rapid prediction of the probability of dying from COVID-19 infection might help triage patients for hospitalization, intensive care, or limited treatment.
Objective To develop a simple tool to estimate the probability of dying from acute COVID-19 illness.
Design, setting and participants This cohort study included 13,190 adult patients admitted to one of the 11 hospitals in the New York City Health + Hospitals system for COVID-19 infection between March 1 and June 30, 2020.
Exposures Demographic characteristics, vital signs, and laboratory tests readily available at the time of hospital admission.
Main outcome Death from any cause during hospitalization.
Results Patients had a mean age (interquartile range) of 58 (45-72) years; 5421 (41%) were women, 5258 Latinx (40%), 3805 Black (29%), 1168 White (9%), and 2959 Other (22%).
During hospitalization, 2,875 (22%) died. Using separate test and validation samples, machine learning (Gradient Boosted Decision Trees) identified eight variables—oxygen saturation, respiratory rate, systolic and diastolic blood pressures, pulse rate, blood urea nitrogen level, age and creatinine—that predicted mortality, with an area under the ROC curve (AUC) of 94%. A score based on these variables classified 5,677 (46%) as low risk (a score of 0) who had 0.8% (95% confidence interval, 0.5 – 1.0%) risk of dying, and 674 (5.4%) as high-risk (score ≥ 12 points) who had a 97.6% (96.5-98.8%) risk of dying; the remainder had intermediate risks. A risk calculator is available online at https://danielevanslab.shinyapps.io/Covid_mortality/).
Conclusions and relevance In a diverse population of hospitalized patients with COVID-19 infection, a clinical prediction model using a few readily available assessments may precisely estimate in-hospital mortality and can rapidly assist decisions to prioritize admissions and intensive care.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The use of the data for the analyses was approved by the Sutter Health I.R.B. and the N.Y.U. Grossman School of Medicine I.R.B.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
1
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos